(Q38025156)

27 August 2017

title

Diagnosis, progression patterns and prognostication in mastocytosis (English)

1 reference

27 August 2017

Wolfgang R Sperr

1

1 reference

27 August 2017

Peter Valent

series ordinal

2

1 reference

27 August 2017

publication date

1 June 2012

1 reference

Expert Review of Hematology

27 August 2017

published in

1 reference

27 August 2017

volume

5

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

261-274

1 reference

Mastocytosis: pathology, genetics, and current options for therapy

27 August 2017

cites work

1 reference

Mast cells and mastocytosis

21 January 2018

1 reference

Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.

21 January 2018

1 reference

How I treat patients with advanced systemic mastocytosis.

21 January 2018

1 reference

Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal

21 January 2018

1 reference

Mast cell activation syndrome: Proposed diagnostic criteria.

21 January 2018

1 reference

Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options

21 January 2018

1 reference

Systemic mastocytosis--definition of an internal disease

21 January 2018

1 reference

Neonatal onset diffuse cutaneous mastocytosis: a case report and review of the literature.

21 January 2018

1 reference

Diagnostic criteria and classification of mastocytosis: a consensus proposal

21 January 2018

1 reference

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

21 January 2018

1 reference

Treatment of systemic mast-cell disease with cladribine

21 January 2018

1 reference

Cladribine therapy for systemic mastocytosis.

21 January 2018

1 reference

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

21 January 2018

1 reference

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

21 January 2018

1 reference

Mast cell mediators in allergic inflammation and mastocytosis

21 January 2018

1 reference

Current options in the treatment of mast cell mediator-related symptoms in mastocytosis

21 January 2018

1 reference

Treatment of cutaneous mastocytosis

21 January 2018

1 reference

The treatment of mastocytosis: an overview

21 January 2018

1 reference

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

21 January 2018

1 reference

Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis.

21 January 2018

1 reference

Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts.

21 January 2018

1 reference

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

21 January 2018

1 reference

Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings.

21 January 2018

1 reference

Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells.

21 January 2018

1 reference

Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature

21 January 2018

1 reference

Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria

21 January 2018

1 reference

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

21 January 2018

1 reference

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

21 January 2018

1 reference

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

21 January 2018

1 reference

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

21 January 2018

1 reference

Systemic mastocytosis with associated clonal hematological non‐mast‐cell lineage disease: Analysis of clinicopathologic features and activating c‐kit mutations

21 January 2018

1 reference

One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes

21 January 2018

1 reference

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior

21 January 2018

1 reference

The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells

21 January 2018

1 reference

Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis

21 January 2018

1 reference

Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation

21 January 2018

1 reference

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.

21 January 2018

1 reference

A germline mutation in KIT in familial diffuse cutaneous mastocytosis

21 January 2018

1 reference

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy

21 January 2018

1 reference

Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis

21 January 2018

1 reference

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.

21 January 2018

1 reference

Interleukin-13 promoter gene polymorphism -1112C/T is associated with the systemic form of mastocytosis

21 January 2018

1 reference

Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria

21 January 2018

1 reference

Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis

21 January 2018

1 reference

Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy

21 January 2018

1 reference

Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis.

21 January 2018

1 reference

Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.

21 January 2018

1 reference

Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review

21 January 2018

1 reference

CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.

21 January 2018

1 reference

Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria

21 January 2018

1 reference

Serum tryptase measurements in patients with myelodysplastic syndromes

21 January 2018

1 reference

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis

21 January 2018

1 reference

Smouldering mastocytosis: a novel subtype of systemic mastocytosis with slow progression

21 January 2018

1 reference

Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia.

21 January 2018

1 reference

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

21 January 2018

1 reference

A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val

21 January 2018

1 reference

Systemic mastocytosis: clinical manifestations and differential diagnosis

21 January 2018

1 reference

Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome.

21 January 2018

1 reference

Clinical and histopathological aspects of cutaneous mastocytosis

21 January 2018

1 reference

Mastocytosis: review of clinical and experimental aspects

21 January 2018

1 reference

Cutaneous mastocytosis -- clinical heterogeneity.

21 January 2018

1 reference

Classification and diagnosis of mastocytosis: current status

21 January 2018

1 reference

Mast cells and mast cell neoplasia: a review

21 January 2018

1 reference

A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men.

21 January 2018

1 reference

Slowly progressive systemic mastocytosis with high mast-cell burden and no evidence of a non-mast-cell hematologic disorder: an example of a smoldering case?

21 January 2018

1 reference

Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management

21 January 2018

1 reference

Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis.

21 January 2018

1 reference

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies

21 January 2018

1 reference

KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation

21 January 2018

1 reference

High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

21 January 2018

1 reference

Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.

21 January 2018

1 reference

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

21 January 2018

1 reference

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

21 January 2018

1 reference

Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.

21 January 2018

1 reference

Antileukotriene drugs: clinical application, effectiveness and safety

21 January 2018

1 reference

Mastocytosis: current concepts in diagnosis and treatment

21 January 2018

1 reference

Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.

21 January 2018

1 reference

Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment

21 January 2018

1 reference

Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.

21 January 2018

1 reference

Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis

21 January 2018

1 reference

"Smoldering systemic mastocytosis. "Successful therapy with cladribine

21 January 2018

1 reference

Response of severe systemic mastocytosis to interferon alpha

21 January 2018

1 reference

KIT mutations in mastocytosis and their potential as therapeutic targets

21 January 2018

1 reference

The liver, spleen, and lymph nodes in mastocytosis

21 January 2018

1 reference

Pathogenesis, clinical features, and treatment advances in mastocytosis.

21 January 2018

1 reference

Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils.

21 January 2018

1 reference

Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells

21 January 2018

1 reference

Clinical and biologic diversity of leukemias occurring in patients with mastocytosis.

21 January 2018

1 reference

Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells

21 January 2018

1 reference

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells

21 January 2018

1 reference

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

21 January 2018

1 reference

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study

21 January 2018

1 reference

Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors

21 January 2018

1 reference

Systemic mastocytosis and bone involvement in a cohort of 75 patients

21 January 2018

1 reference

Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor

21 January 2018

1 reference

Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.12.12

1 reference

27 August 2017

1 reference